BLRD Research Career Scientist Award Application

该提案旨在更新Subhra博士持有的研究职业科学家奖 莫哈帕特拉，在詹姆斯A。自2018年以来，在佛罗里达坦帕的Haley VA医院。她也是一位终身教授- 弗吉尼亚大学附属学术中心-南佛罗里达大学的全职教授（兼职）。她 是几个国际/国家奖项和荣誉的获得者，包括作为研究员， 美国国家发明家学院和美国医学和生物研究所的研究员 工程. Mohapatra博士自2009年以来一直是VA医院（医学）的研究调查员。 2007年，并一直与重点关注癌症，创伤， 自2016年以来，脑损伤（TBI）和COVID。她一直在研究基本的分子， 在不同的急性/慢性疾病，包括炎症的翻译机制 COVID-19，癌症和TBI，所有这些都困扰着VA人口，并对VA人口的增长做出了重大贡献。 退伍军人的整体健康。她研究计划的主要前提是 了解疾病发病机制中涉及的机制， 诊断/预后和治疗方法来治疗它们。当前和正在进行的研究 该RCS奖支持的活动集中在三个领域。第一个项目的中心是 可以用作预防和/或治疗的新型病毒中和纳米颗粒的表征 治疗新冠肺炎患者。在这个提议中，将研究这些粒子的潜力， 并在相关的人类细胞和小鼠模型中得到验证。她正在与其他VA合作 研究人员正在开发一个额外的项目，以开发新的基于siRNA的预防和 针对急性SARS后病毒复制和细胞因子风暴的治疗方法- CoV-2感染。第二个研究项目的重点是对一部小说的调查 在中度TBI的小鼠模型中的组合治疗方法，其包括鼻内给药， 针对最近发现的靶点CCL 20的基于树枝状聚合物的纳米配制siRNA治疗， 减少炎症，以及通过以下疗法促进神经再生的平行治疗： 间充质干细胞在第三个研究项目中，莫哈帕特拉博士的实验室旨在研究 并测试一种新的靶向溶瘤病毒细胞治疗肺癌的方法， 细胞感染呼吸道合胞病毒感染，这是无害的免疫活性 个体该项目使用体外3D多细胞类肿瘤和离体活检衍生的培养物， 这是她的实验室开创的。此外，该项目使用体内肺癌小鼠模型， 评估溶瘤病毒细胞疗法的安全性和有效性。该项目迄今已吸引了 行业合作，这可能会导致临床试验。总的来说，这些高度创新的 这些方法结合在一起，有望产生高影响力的临床诊断和治疗方法。 为退伍军人和其他有需要的美国人提供各种疾病。退伍军人已经 受大流行病影响的比例越来越高， 与普通人群相比，癌症和TBI。拥有约100篇出版物，20项专利，一个h- 指数为36，i指数为85，Subhra Mohapatra博士在全国范围内得到认可， 国际上对癌症，神经退行性疾病， 和病毒感染。她获得了大量的校外研究支持，包括奖项 来自NIH、ONR、退伍军人事务部和佛罗里达卫生部。是 预计这些有效疗法的发展将大大提高质量， 退伍军人的医疗保健。

This proposal seeks to renew Research Career Scientist Award held by Dr. Subhra Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2018. She is also a tenured- full professor (part-time) at the VA-affiliated academic center- the University of South Florida. She is the recipient of several international/national awards and recognitions including as a Fellow of the National Academy of Inventors and a Fellow of the American Institute for Medical and Biological Engineering. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 2007 and has been continuously funded with the Merit Review Award focused on cancer, traumatic brain injury (TBI), and COVID since 2016. She has been studying the basic molecular and translational mechanisms underlying the inflammation in diverse acute/chronic diseases including COVID-19, cancers, and TBI, all of which afflict VA population and contribute significantly to the overall health of the Veterans. The main premise of her research program has been to understand the mechanisms involved in the disease pathogenesis toward developing novel diagnostic/prognostic and therapeutic approaches to treat them. Current and ongoing research activities to be supported by this RCS Award focus on three areas. The first program centers on the characterization of novel virus-neutralizing nanoparticles that may serve as prophylactic and/or treatment for COVID-19 patients. In this proposal, these particles will be investigated for their potential and validated in relevant human cellular and mouse models. She is collaborating with other VA investigators in developing an additional project to develop novel siRNA-based prophylactic and therapeutic approaches targeting viral replication and cytokine storm that follows acute SARS- CoV-2 infection. The second research program focuses on the investigation of a novel combinatorial therapeutic approach in a mouse model of moderate TBI that includes an intranasal dendrimer-based nano-formulated siRNA treatment against a recently discovered target, CCL20 to reduce inflammation, and a parallel treatment to promote neuroregeneration by therapy with mesenchymal stem cells. In the third research program Dr. Mohapatra’s lab aims to investigate and test a novel targeted oncolytic viro-cell therapy for lung cancer using the mesenchymal stem cells infected by a respiratory syncytial virus infection, which is harmless for immunocompetent individuals. This project uses a 3D multicell tumoroid in vitro and biopsy-derived cultures ex vivo, which her lab has pioneered. Further, this project uses in vivo mouse models of lung cancer to evaluate the safety and efficacy of oncolytic viro-cell therapy. The project to date has attracted industry collaboration, which might lead to clinical trials. Overall, these highly innovative approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for diverse diseases of Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. With ~100 publications, 20 patents, an h- index of 36 and an i-index of 85, Dr. Subhra Mohapatra is recognized nationally and internationally for her contributions to the fields of research on cancer, neurodegenerative disease, and viral infections. She has received substantial extramural research support including awards from the NIH, ONR, Department of Veterans Affairs, and Florida Department of Health. It is anticipated that the development of these effective therapeutics will greatly improve the quality of Veteran’s healthcare.